Chemical inhibition of fatty acid synthase: Molecular docking analysis and biochemical validation in ocular cancer cells

Journal of Ocular Biology, Diseases, and Informatics

Volumn 3, Issue 4, 2010, Pages 117-128

  Deepa, P R ^a   Vandhana, S ^a,b   Muthukumaran, S ^b   Umashankar, V ^b   Jayanthi, U ^b   Krishnakumar, S ^b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b VISION RESEARCH FOUNDATION   (India)

Author keywords

Cerulenin; Cytotoxicity; Fatty Acid Synthase; Molecular Docking; Orlistat; Retinoblastoma; Triclosan

Indexed keywords

CERULENIN; FATTY ACID SYNTHASE; TETRAHYDROLIPSTATIN; TRICLOSAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG BINDING; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; RETINOBLASTOMA; SEQUENCE HOMOLOGY; SIMULATION;

EID: 84856423523     PISSN: 19368437     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-011-9065-7     Document Type: Article

References (32)

1. Murray RK, Graner DK, Rodwell VW. Harper's illustrated biochemistry. USA: Mc Graw Hill Inc; 2009.
2. Vandhana S, Deepa PR, Jayanthi U, Biswas J, Krishnakumar S. Clinico-pathological correlations of fatty acid synthase expression in retinoblastoma: an Indian cohort study. Exp Mol Pathol. 2011;90:29-37.
3. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci. 1994;91:6379-83. (Pubitemid 24200664)
4. Liu B, Wang Y, Fillgrove KL, Anderson VE. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol. 2002;49:187-93. (Pubitemid 34185591)
5. Steven JK, Fumiko A, Natasha R, Jeffrey WS. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070-5.
6. Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp. 2004;52:414-26. (Pubitemid 40123231)
7. Lu S, Archer MC. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis. 2005;26:153-7. (Pubitemid 40207710)
8. Vandhana S, Deepa PR, Aparna G, Jayanthi U, Krishnakumar S. Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan-a hydrophobic drug in cell culture. Indian J Biochem Biophys. 2010;47:166-71.
9. Dils R, Carey EM. Fatty acid synthase from rabbit mammary gland. Methods Enzymol. 1975;35:74-83.
10. Fiser A, Sali A. Modeller: generation and refinement of homology-based protein structure models. Meth Enzymol. 2003;374:461-91. (Pubitemid 37531821)
11. Summa CM, Levitt M. Near-native structure refinement using in vacuo energy minimization. Proc Natl Acad Sci USA. 2007;104:3177-82. (Pubitemid 46364133)
12. Laskowski A, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. R J Biomol NMR. 1996;8:477-86. (Pubitemid 126706801)
13. Pappenberger G, Benz J, Gsell B, Hennig M, Ruf A, Stihle M, et al. Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J Mol Biol. 2010;397:508-19.
14. Zeng XF, Li WW, Fan HJ, Wang XY, Ji P, Wang ZR, et al. Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain. Bioorg Med Chem Lett. 2011;21:4742-4.
15. Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase. Science. 2008;321:1315-22.
16. Pemble CW, Johnson LC, Kridel SJ, Lowther WT. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by orlistat. Nat Struct Mol Biol. 2007;14:704-9. (Pubitemid 47220052)
17. Morris GMGD, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-62. (Pubitemid 128590223)
18. Jenwitheesuk E, Samudrala R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir Ther. 2005;10:157-66. (Pubitemid 40767641)
19. Benkert P, Künzli M, Schwede T. QMEAN server for protein model quality estimation. Nucleic Acids Res. 2009;375:10-4. (Web Server issue).
20. Kuhajda FP. Fatty acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202-8. (Pubitemid 30114274)
21. Camassei FD, Cozza R, Acquaviva A, Jenkner A, Ravà L, Gareri R, et al. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Investig Ophthalmol Vis Sci. 2003;44:2399-403. (Pubitemid 36618394)
22. Ho TS, Ho YP, Wong WY, Chi-Ming Chiu L, Wong YS, Eng-Choon Ooi. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother. 2007;61:578-87. (Pubitemid 47562696)
23. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun. 2001;285:217-23. (Pubitemid 32918056)
24. Kubinyi H. Hydrogen bonding: the last mystery in drug design? In: Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic optimization in drug research: biological, physicochemical, and computational strategies. Zürich: Verlag Helvetica Chimica Acta; 2007.
25. Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998;1:4-15. (Pubitemid 128731837)
26. Wang X, Lin J, Chen Y, Zhong W, Zhao G, Liu H, et al. Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies. Bioorg Med Chem. 2009;17:1898-904.
27. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA. 2000;97:3450-4. (Pubitemid 30183323)
28. Orita H, Coulter J, Lemmon C, Tully E, Vadlamudi A, Medghalchi SM, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res. 2007;13:7139-45. (Pubitemid 350276900)
29. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763-77. (Pubitemid 47469806)
30. Ballinger A, Peikin SR. Orlistat: its current status as an antiobesity drug. Eur J Pharmacol. 2002;440:109-17. (Pubitemid 34458018)
31. Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One. 2010;5:e12029.
32. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the antiobesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005;16:1253-67. (Pubitemid 41166507)